FDA approves first membranous nephropathy drug - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves first membranous nephropathy drug

  • By

  • Mouj Hijazi

  • November 16, 2026

  • 2 min

Share

Clinical Scorecard: FDA approves first membranous nephropathy drug

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: FDA approves first membranous nephropathy drug
Key MechanismsMechanisms or clinical associations described in the source article.
Target PopulationPopulation described in the source article.
Care SettingFDA-approved treatment to induce proteinuria remission in adults with primary membranous nephropathy at risk of disease progression; MAJESTY compared intravenous obinutuzumab with oral tacrolimus.

Key Highlights

  • Obinutuzumab (Gazyva) is the first FDA-approved treatment specifically indicated to induce remission of proteinuria in adults with primary membranous nephropathy at risk of progression.
  • In the 142-participant MAJESTY trial, complete remission at week 104 occurred in 36.1% of obinutuzumab recipients and 5.7% of tacrolimus recipients.
  • Overall remission at week 104 occurred in 50% of obinutuzumab recipients and 12.9% of tacrolimus recipients.
  • The trial did not show a statistically significant difference in sustained eGFR decline of at least 30%; later endpoints in the prespecified testing hierarchy were not formally assessed for significance.
  • FDA-identified common side effects included infusion-related reactions and upper respiratory tract infections; boxed warnings include hepatitis B virus reactivation and progressive multifocal leukoencephalopathy.

Guideline-Based Recommendations

Diagnosis

  • The MAJESTY trial defined complete remission at week 104 as a urine protein-to-creatinine ratio of 0.3 g/g or lower with stable eGFR, without rescue therapy, treatment failure, or early discontinuation.

Management

  • Obinutuzumab is FDA-approved for adults with primary membranous nephropathy at risk of progression to induce remission of proteinuria.
  • The MAJESTY trial compared intravenous obinutuzumab with oral tacrolimus, which was used off-label for this condition.

Monitoring & Follow-up

  • Screen for hepatitis B before treatment and monitor for reactivation during and after treatment.
  • Watch for symptoms of progressive multifocal leukoencephalopathy and manage infusion-related reactions.

Risks

  • Obinutuzumab carries boxed warnings for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy.
  • Avoid administration in patients with active infections.
  • In MAJESTY, grade 3 or higher adverse events occurred in 22% of obinutuzumab recipients and 19% of tacrolimus recipients; serious adverse events occurred in 17% and 14%, respectively.

Patient & Prescribing Data

Adults with primary membranous nephropathy at risk of disease progression.

In MAJESTY, 36.1% of patients receiving obinutuzumab achieved complete remission at week 104 versus 5.7% receiving tacrolimus; overall remission was 50% versus 12.9%. Common side effects reported by the FDA included infusion-related reactions and upper respiratory tract infections.

Clinical Best Practices

  • Screen for hepatitis B before starting obinutuzumab and monitor for reactivation during and after treatment.
  • Monitor for symptoms of progressive multifocal leukoencephalopathy and manage infusion-related reactions.
  • Do not administer obinutuzumab to patients with active infections.

Related Resources & Content

Original Source(s)

Related Content